China Pharma Holdings, Inc. (CPHI): Total Liabilities
$8.26M
As of 2025-12-31
$8.53M
As of 2026-06-30
-15.1%
3-year compound annual growth
-8.8%
5-year compound annual growth
-10.1%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.26M | +15.7% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $7.14M | -20.8% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $9.01M | -33.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $13.49M | -18.9% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $16.63M | +26.8% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $13.11M | +0.9% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $13.00M | -14.4% | 2021-03-26, Balance as of period end |
| 2018-12-31 | $15.18M | -10.1% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $16.88M | -13.9% | 2019-03-28, Balance as of period end |
| 2016-12-31 | $19.61M | -17.9% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $23.87M | n/c | 2017-03-31, Balance as of period end |
| 2014-12-31 | $28.34M | +14.9% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $24.67M | +67.5% | 2015-12-28, Balance as of period end |
| 2012-12-31 | $14.72M | +5.9% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $13.91M | +0.7% | 2013-03-14, Balance as of period end |
| 2010-12-31 | $13.81M | n/a | 2012-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $8.26M | +15.7% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.66M | +20.0% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $56.36M | +0.9% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $2.27M | -34.4% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $70.10M | +362.3% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $4.57M | +106.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $968.0K | +8.2% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $14.00M | +18.0% |
Compare CPHI, CRVO, PRPH, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗